Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Drug Safety Update - August 2016

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for August 2016 (PDF).

Following early termination of a clinical trial it is recommended that riociguat (Adempas®) should not be used to treat patients with pulmonary hypertension associated with idiopathic interstitial pneumonias. This medication should be under specialist supervision.

There is also a summary of letters sent to healthcare professionals in July including a letter advised that posaconazole (Noxafil®) tablets and suspension are not interchangeable and that inadvertent changes between the two formulations has led to under-dosing or over-dosing.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'Drug Safety Update - August 2016' on Email Share 'Drug Safety Update - August 2016' on Delicious Share 'Drug Safety Update - August 2016' on Digg Share 'Drug Safety Update - August 2016' on Facebook Share 'Drug Safety Update - August 2016' on Google+ Share 'Drug Safety Update - August 2016' on reddit Share 'Drug Safety Update - August 2016' on StumbleUpon Share 'Drug Safety Update - August 2016' on Twitter

atomic-wealth

One Comments to “Drug Safety Update - August 2016”

  1. […] This issue also contains additional information that posaconazole suspension and tablets are not dose equivalent as noted in the summary of letters to healthcare professionals in last month's update. […]

    Pingback by Drug Safety Update - September 2016 - Prescribing Advice For GPs — September 19, 2016 #
    Reply

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,518 spam comments.

atomic-wealth
fond-illness
summer